Abstract:Anaplastic thyroid cancer (ATC) is one of the most lethal cancers. Although dramatic responses to BRAFV600E-mutated ATC are seen with BRAF/MEK inhibition, treatment resistance inevitably develops, limiting survival. In this study we sequentially profiled BRAFV600E-mutated ATC at diagnosis, after BRAF/MEK targeted therapy and at the time of disease recurrence using both bulk and single-cell DNA/RNA sequencing. We profiled (~400-800 single cells) for each patient - Patient 1 (n = 704 cells); Patient 2 (n = 817 cells) and Patient 3 (n = 407 cells). At diagnosis, we show that tumor cell populations were characterized by a predominance of arm-level aneuploidies. Across all patients, there is a sharp decline in tumor cells post BRAF-targeted treatment. Interestingly, we observe at least 2 distinct tumor subclones present in the pre-treatment tumor and subsequently there was an expansion event that occurred in each patient after BRAF treatment. This was associated with acquiring unique copy number aberrations (CNA)events and the dominance of these subclones in the recurrent disease. For Patient 2, we also performed single-cell RNA sequencing and show that the recurrent tumor cells have high proliferation and stem-cell like cell states even though they had higher differentiation scores. Importantly, correlating the scDNAseq identified CNA with the inferred CNA from scRNAseq, we show proof of concept that copy number aberrations can be directly correlated with gene expression changes and gene dosage effects. Collectively our data reveal an early polyclonal dissemination model of clones in BRAF-mutated ATCs and suggests that treatment resistance to BRAF inhibition develops as a results of incomplete elimination of viable tumor cell reservoirs in ATC. Citation Format: Aatish Thennavan, Maxime Tarabichi, Per Wu, Meghan Martin, Ramona Dadu, Maria Cabanillas, Nafia Busaidy, Ying C. Henderson, Mark Zafereo, Michelle D. Williams, Stephen Lai, Nicholas Navin, Jennifer R. Wang. Single cell DNA sequencing of BRAF treatment resistant anaplastic thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6216.

Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy

Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma

Table S1 from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>med12</i> and <i>rbm10</i> As Novel Thyroid Cancer Genes Associated with Tumor Virulence

The Role of BRAF in the Pathogenesis of Thyroid Carcinoma.

Supplementary Figure 1 from Detection and Dynamic Changes of <i>egfr</i> Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Abstract 6216: Single cell DNA sequencing of BRAF treatment resistant anaplastic thyroid cancer

Supplementary Table S1 and Figure Legends from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Uncommon molecular alterations in follicular-derived thyroid carcinoma: A single institution study

The Prevalence and Prognostic Implications of BRAF K601E Mutations in Thyroid Neoplasms: A Systematic Review and Meta‐Analysis

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy

Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan

Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma

Abstract 2276: Comprehensive analysis of the genomic landscape of thyroid cancer

Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Supplementary Table S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Targetable Treatment Resistance in Thyroid Cancer with Clonal Hematopoiesis

Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer

A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma

Genomic alterations in thyroid cancer: biological and clinical insights